188 related articles for article (PubMed ID: 15835270)
1. Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway.
Abel TW; Baker SJ; Fraser MM; Tihan T; Nelson JS; Yachnis AT; Bouffard JP; Mena H; Burger PC; Eberhart CG
J Neuropathol Exp Neurol; 2005 Apr; 64(4):341-9. PubMed ID: 15835270
[TBL] [Abstract][Full Text] [Related]
2. Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults.
Zhou XP; Marsh DJ; Morrison CD; Chaudhury AR; Maxwell M; Reifenberger G; Eng C
Am J Hum Genet; 2003 Nov; 73(5):1191-8. PubMed ID: 14566704
[TBL] [Abstract][Full Text] [Related]
3. Lhermitte-Duclos disease and Cowden disease: clinical and genetic study in five patients with Lhermitte-Duclos disease and literature review.
Pérez-Núñez A; Lagares A; Benítez J; Urioste M; Lobato RD; Ricoy JR; Ramos A; González P
Acta Neurochir (Wien); 2004 Jul; 146(7):679-90. PubMed ID: 15197611
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.
Xu G; Zhang W; Bertram P; Zheng XF; McLeod H
Int J Oncol; 2004 Apr; 24(4):893-900. PubMed ID: 15010827
[TBL] [Abstract][Full Text] [Related]
5. Severe Lhermitte-Duclos disease with unique germline mutation of PTEN.
Sutphen R; Diamond TM; Minton SE; Peacocke M; Tsou HC; Root AW
Am J Med Genet; 1999 Feb; 82(4):290-3. PubMed ID: 10051160
[TBL] [Abstract][Full Text] [Related]
6. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma.
Hu X; Pandolfi PP; Li Y; Koutcher JA; Rosenblum M; Holland EC
Neoplasia; 2005 Apr; 7(4):356-68. PubMed ID: 15967113
[TBL] [Abstract][Full Text] [Related]
7. A heterozygous frameshift mutation of the PTEN/MMAC1 gene in a patient with Lhermitte-Duclos disease - only the mutated allele was expressed in the cerebellar tumor.
Iida S; Tanaka Y; Fujii H; Hayashi S; Kimura M; Nagareda T; Moriwaki K
Int J Mol Med; 1998 Jun; 1(6):925-9. PubMed ID: 9852626
[TBL] [Abstract][Full Text] [Related]
8. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
Neshat MS; Mellinghoff IK; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons JJ; Wu H; Sawyers CL
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10314-9. PubMed ID: 11504908
[TBL] [Abstract][Full Text] [Related]
9. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi Y; Gera J; Hu L; Hsu JH; Bookstein R; Li W; Lichtenstein A
Cancer Res; 2002 Sep; 62(17):5027-34. PubMed ID: 12208757
[TBL] [Abstract][Full Text] [Related]
10. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology.
Griffin RJ; Moloney A; Kelliher M; Johnston JA; Ravid R; Dockery P; O'Connor R; O'Neill C
J Neurochem; 2005 Apr; 93(1):105-17. PubMed ID: 15773910
[TBL] [Abstract][Full Text] [Related]
11. Cowden disease and Lhermitte-Duclos disease: characterization of a new phakomatosis.
Robinson S; Cohen AR
Neurosurgery; 2000 Feb; 46(2):371-83. PubMed ID: 10690726
[TBL] [Abstract][Full Text] [Related]
12. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.
Ozes ON; Akca H; Mayo LD; Gustin JA; Maehama T; Dixon JE; Donner DB
Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4640-5. PubMed ID: 11287630
[TBL] [Abstract][Full Text] [Related]
13. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome.
Panigrahi AR; Pinder SE; Chan SY; Paish EC; Robertson JF; Ellis IO
J Pathol; 2004 Sep; 204(1):93-100. PubMed ID: 15307142
[TBL] [Abstract][Full Text] [Related]
14. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway.
Zhou XP; Waite KA; Pilarski R; Hampel H; Fernandez MJ; Bos C; Dasouki M; Feldman GL; Greenberg LA; Ivanovich J; Matloff E; Patterson A; Pierpont ME; Russo D; Nassif NT; Eng C
Am J Hum Genet; 2003 Aug; 73(2):404-11. PubMed ID: 12844284
[TBL] [Abstract][Full Text] [Related]
15. Role of PTEN, a lipid phosphatase upstream effector of protein kinase B, in epithelial thyroid carcinogenesis.
Eng C
Ann N Y Acad Sci; 2002 Jun; 968():213-21. PubMed ID: 12119278
[TBL] [Abstract][Full Text] [Related]
16. Lhermitte-Duclos disease as a component of Cowden's syndrome. Case report and review of the literature.
Koch R; Scholz M; Nelen MR; Schwechheimer K; Epplen JT; Harders AG
J Neurosurg; 1999 Apr; 90(4):776-9. PubMed ID: 10193626
[TBL] [Abstract][Full Text] [Related]
17. Brain magnetic resonance imaging in patients with Cowden syndrome.
Lok C; Viseux V; Avril MF; Richard MA; Gondry-Jouet C; Deramond H; Desfossez-Tribout C; Courtade S; Delaunay M; Piette F; Legars D; Dreno B; Saïag P; Longy M; Lorette G; Laroche L; Caux F;
Medicine (Baltimore); 2005 Mar; 84(2):129-136. PubMed ID: 15758842
[TBL] [Abstract][Full Text] [Related]
18. PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes
Makker A; Goel MM; Mahdi AA; Bhatia V; Das V; Agarwal A; Pandey A
Indian J Med Res; 2016 May; 143(Supplement):S112-S119. PubMed ID: 27748285
[TBL] [Abstract][Full Text] [Related]
19. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
Kurose K; Zhou XP; Araki T; Cannistra SA; Maher ER; Eng C
Am J Pathol; 2001 Jun; 158(6):2097-106. PubMed ID: 11395387
[TBL] [Abstract][Full Text] [Related]
20. Lhermitte-Duclos Disease in association with Cowden Syndrome.
Nielson C; Fischer T; Fischer R; Donald J; Rajpara A
Dermatol Online J; 2016 May; 22(5):. PubMed ID: 27617518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
